2022 Fiscal Year Final Research Report
Development of CO2 generating nanoparticles for pancreatic cancer theranostics
| Project/Area Number |
20K16093
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | CO2産生ナノ粒子 / がん治療 |
|---|
| Outline of Final Research Achievements |
CO2 generating-lipid nanoparticles (CO2-L) which were composed of phospholipid (DPPC and MSPC), and PEG-lipid were prepared by thin film method. To encapsulate doxorubicin as a anti-tumor agent, pH gradient remote loading procedure was used. In addition, to generate carbon dioxide (CO2), ammonium bicarbonate (ABC) was used. The encapsulation efficiency of dox is about 80%. The CO2-L showed the drug release triggered via mild hyperthermia (42℃). Moreover, the cytotoxicity of combination of CO2-L and mild hyperthermia is higher than that of combination of control liposomes and mild hyperthermia. Therefore, CO2-L might be a useful tools for cancer theranostics using ultrasound.
|
| Free Research Field |
ドラッグデリバリーシステム
|
| Academic Significance and Societal Importance of the Research Achievements |
ドキソルビシンとABCを共に封入できる脂質ナノ粒子の作製に成功し、加温に伴ってCO２の産生及びCO2産生によりドキソルビシンの放出が促され、ABCを含まないリポソームと比較して高い殺細胞効果を得ることができた。以上、温度に応答することでCO2を産生することから、外部エネルギーを利用したがんの診断・治療システムを可能とし得る新たなナノ粒子として、医療に貢献するものと期待される。
|
